Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;53(4):381-6.

Efficacy of enrofloxacin in a mouse model of sepsis

Andrea R Slate  1 , Sheila Bandyopadhyay  2 , Kevin P Francis  3 , Mark G Papich  4 , Brian Karolewski  5 , Eldad A Hod  2 , Kevin A Prestia  6
Affiliations

Efficacy of enrofloxacin in a mouse model of sepsis

Andrea R Slate et al. J Am Assoc Lab Anim Sci. 2014 Jul.

Abstract

We examined the efficacy of enrofloxacin administered by 2 different routes in a mouse model of sepsis. Male CD1 mice were infected with a bioluminescent strain of enteropathogenic Escherichia coli and treated with enrofloxacin either by injection or in drinking water. Peak serum levels were evaluated by using HPLC. Mice were monitored for signs of clinical disease, and infections were monitored by using bioluminescence imaging. Serum levels of enrofloxacin and the active metabolite ciprofloxacin were greater in the group treated by injection than in controls or the groups treated by administration in drinking water. Survival of the group treated with enrofloxacin injection was greater than that of controls and groups treated with enrofloxacin in the drinking water. Bioluminescence in the group treated with enrofloxacin injection was less than that in the groups treated with oral administration at 12 h and in the groups treated orally and the control group at 16 h. According to these findings, we recommend the use of injectable enrofloxacin at 5 mg/kg SC for mice with systemic infections.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Serum (A) enrofloxacin and (B) ciprofloxacin levels in mice 2 h after the last injection or 24 h after addition of antibiotic to drinking water. (n = 5 for each group). *, P < 0.05; †, P < 0.01; ‡, P < 0.001.
Figure 2.
Figure 2.
Representative in vivo images of antibiotic treated mice obtained for 24 h after intraperitoneal bacterial challenge with 1 × 108 CFU E. coli Xen 14.
Figure 3.
Figure 3.
Survival curve of antibiotic treated mice challenged with E. coli Xen 14. (n = 16 each for saline control group and enrofloxacin 5 mg/kg SQ, n = 14 each for enrofloxacin in drinking water at 0.05 and 0.1 mg/mL). Survival of group treated with 5 mg/kg SQ is significantly greater (†, P < 0.01) than all other groups.
Figure 4.
Figure 4.
Bioluminescence of region of interest (mean ± 1 SD) of antibiotic-treated mice challenged with E. coli Xen 14. (n = 16 each for saline control group and enrofloxacin 5 mg/kg SC; n = 14 each for enrofloxacin in drinking water at 0.05 and 0.1 mg/mL). Bioluminesence of group treated with 5 mg/kg SC is significantly lower than both groups dosed in drinking water at 12 h postinfection (ϕ, P < 0.05) and to both groups dosed in water as well as the saline control group at 16 h postinfection (*, P < 0.05).
See this image and copyright information in PMC

References

    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310 - PubMed
    1. Aucoin D. 2007. Target: the antimicrobial reference guide to effective treatment, 3rd ed. Port Huron (MI): North American Compendiums.
    1. Barbier M, Damron FH, Bielecki P, Suárez-Diez M, Puchałka J, Albertí S, Martins dos Santos V, Goldberg JB. 2014. From the environment to the host: re-wiring of the transcriptome of Pseudomonas aeruginosa from 22° C to 37° C. PloS One 9:e89941. - PMC - PubMed
    1. Black-Schultz L, Coatney RW, Warnick CL, Swif B. 1997. Lack of reactivation of shigellosis in naturally infected enrofloxacin-treated cynomolgus monkeys after exogenous immunosuppression. Lab Anim Sci 47:602–605 - PubMed
    1. Blondeau JM, Borsos S, Blondeau L, Blondeau B. 2012. In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. Vet Microbiol 155:284–290 - PubMed

MeSH terms